•         

CDCap™ Human CpG Island Panel Kit

CAT Size Inquiry Basket
PNM001-1 24rxn
PNM001-2 96rxn
Overview

Product Description

The CDCap™ Human CpG Island Panel delivers precise and efficient detection of DNA methylation modifications in human genomic DNA. By targeting 27,000 CpG islands and 13 commercial methylation markers for enrichment, this panel serves as a high-performance tool for diverse methylation research.

Features

Key Features & Advantages

Ultra-High Coverage
· Targets 27,000 CpG Islands, 2.03 million CpG sites, and 13 commercial methylation markers.
Enhanced Performance with Dual-Strain Design
· Dual-strain dual-methyl status design enables robust amplification while reducing costs.
High Sensitivity and Compatibility
· Compatible with multiple sample types (e.g., blood, tissue, cell lines, FFPE), delivering robust results even with low-input or partially degraded DNA.
Precise and Reproducible Results
· Optimized conversion and detection workflows ensure highly accurate methylation level measurements with excellent reproducibility.

Specifications

Product Specifications

Enrichment Method: Probe Hybridization Capture
Species: Human
Variant Types: 27,000 CpG islands and 13 methyl marker regions
Target Size: 21.2Mb
Sample Type: Tissue、FFPE、blood etc.
Method: NGS
Sequencing Platform: Illumina
Storage: Store at -20 °C.
Data

Data

1. Excellent Performance

The CDCap™ Human CpG Island Panel demonstrates consistent performance across diverse sample types, including NA12878 reference DNA, FFPE-derived DNA, and simulated cfDNA (fragmented NA12878) at varying input amounts. Validation data confirm high reproducibility in methylation detection regardless of sample origin or quality.

2. Highly Correlated with WGBS

Comparative analysis revealed strong correlation (r>0.95) between methylation levels detected by the CDCap™ Human CpG Island Panel and whole-genome bisulfite sequencing (WGBS), establishing this panel as a robust alternative for comprehensive methylation profiling.

3. Excellent Reproducibility

Inter-run validation studies showed minimal variance in methylation calling across replicate experiments, confirming the technical reliability of the CDCap™ Human CpG Island Panel for longitudinal methylation monitoring.

* For research purposes only, not intended for clinical diagnosis, treatment, or individual health assessments.
Copyright © 2026 CD Genomics. All rights reserved.
Top
0
Inquiry Basket